Alleviating stuttering with pharmacological interventions

Bibliography

• AMERICAN PSYCHIATRICASSOCIATION: Diagnostic and statistical manual of mental disorders: DSM-IV-TR. fourth edition, text revision. American Psychiatric Association, Washington, DC, USA (2000).
   Google Scholar
• MAGUIRE GA, RILEY GD,FRANKLIN DL et al.: The dopamine hypothesis of stuttering and its treatment implications. Int. I Neuropsychopharmacol (2000) 3 (Suppl. 1).
   Google Scholar
• STEIN MB, BAIRD A, WALKER JR: Social phobia in adults with stuttering. Am. .1. Psychiatry (1996) 153(2):278–280.
   Google Scholar
• LUDLOW CL, DOOMAN AG: Genetic aspects of idiopathic speech and language disorders. Otolaryngol Clin. North Am. (1992) 25(5):979–994.
   PubMed Web of Science ®Google Scholar
• MANNING WH: Clinical decision making in fluency disorders, second edition. Singular, San Diego, CA, USA (2001):107–108.
   Google Scholar
• ANDREWS G, CRAIG A, FEYER A, HODDINOTT S, HOWIE P,NEILSON M: Stuttering: a review of research findings and theories circa 1982. .1. Speech Hear. Disord. (1983) 48:226–263.
   Google Scholar
• RILEY G, INGHAM J: Acoustic duration changes associated with two types of treatment for children who stutter. Speech Hear. Disord. (2000) 43:965–978.
   Google Scholar
• MAGUIRE GA, RILEY GD, FRANKLIN DL, GOTTSHALK LA: Risperidone for the treatment of stuttering. Psychopharmacol (2000) 20:479–482.
   Web of Science ®Google Scholar
• WU JC, MAGUIRE GA, RILEY G et al.: A positron emission tomography [18F] deoxyglucose study of developmental stuttering. Neuroreport (1995) 6:501–505.
   PubMed Web of Science ®Google Scholar
• FELSENFELD S, KIRK KM, ZHU G, STATHAM DJ, NEALE MC,MARTIN, NG: A study of the genetic and environmental etiology of stuttering in a selected twin sample. Behav. Genet. (2000) 30(5):359–366.
   PubMedGoogle Scholar
• HOWIE PM: Concordance for stuttering in monozygotic and dizygotic twin pairs. Speech Hear. Disord. (1981) 24(3):317–321.
   Google Scholar
• SHUGART YY, MUNDORFF J, KILSHAW J et al.: Results of a genome-wide linkage scan for stuttering. Am. .1. Med. Genet. (2004) 124A(2):133–135.
   Google Scholar
• ORTON ST: Studies in Stuttering. Arch. Nemo]. Psychiatry (1927) 18:671–672.
   Google Scholar
• TRAVIS LE: Speech pathology. Appleton-Century-Crofts, New York, USA (1931).
   Google Scholar
• SADOCK BJ, SADOCK VA: Kaplan and Sadock's Comprehensive Textbook of Psychiatry (7th edit). Lippincott Williams &Wilkins (2000).
   Google Scholar
• MANNING WH: Clinical decision making in fluency disorders, second edition. Singular, San Diego, CA, USA (2001):311–314.
   Google Scholar
• WU JC, MAGUIRE G, RILEY G, LEE A, KEATOR D, TANG C, FALLON J, NAJAFI A: Increased dopamine activity associated with stuttering.Neuroreport (1997) 8(3):767–70.
   PubMed Web of Science ®Google Scholar
• WU JC, RILEY GD, MAGUIRE GA, NAJAFI A, TANG C: Pet scan evidence of parallel cerebral systems related to treatment effects: fdg and fdopa PET scan findings. In: Speech Production: motor control, brain research and fluency disorders. W Hulstijn Peters HFM, Van Lieshout PHHM (Ecia), Elsvier Science, Amsterdam,The Netherlands.
   Google Scholar
• WOOD F, STUMP D: Patterns of regionalcerebral blood flow during attempted reading aloud by stutters both on and off haloperidol medication: evidence forinadequate left frontal activation during stuttering. Brant Lang. (1980) 9:141–144.
   PubMed Web of Science ®Google Scholar
• POOL KD, DEVOUS MD,FREEMAN FJ, WATSON BC,FINITZO T: Regional cerebral blood flow in developmental stutterers. Arch. Neurol (1991) 48:509–512.
   PubMed Web of Science ®Google Scholar
• NUDELMAN HB, HERBRICH KE, HESS KR, HOYT BD,ROSENFIELD DB: A model of the phonatory response time of stutterers and fluent speakers to frequency-modulated tones. J. Acoust. Soc. Am. (1992) 92(4 Pt 1):1882–1888.
   Google Scholar
• NEUMANN K, EULER H,VON GUDENBERG W et al.: The nature and treament of stuttering as revealed by fMRI A within- and between-group comparison. Fluency Disorders (2003) 28:381–410.
   Google Scholar
• BURD L, KERBESHIAN J: Stuttering andstimulants [letter]. J. Clin. Psychopharmacol (1991) 11(1):72–73.
   PubMedGoogle Scholar
• MAGUIRE GA: The dopamine hypothesis of stuttering and its treatment implications. Presented at Collegium Internationale Neuro-Psychopharmacologicum, Brussels, Belgium, July (2000).
   Google Scholar
• FOUNDAS AL, BOLLICH AM, COREY DM, HURLEY M,HEILMAN KM: Anomalous anatomy of speech-language areas in adults with persistent developmental stuttering. Neurology (2001) 57:207–215.
   PubMed Web of Science ®Google Scholar
• SOMMER M, KOCH MA, PAULUS W, VVEILLER C, BUCHEL C: Disconnection of speech-relevant brain areas in persistent developmental stuttering. Lancet (2002) 360:380–383.
   PubMed Web of Science ®Google Scholar
• RILEY G: Stuttering severity instrument Ord edn). ProEd, Austin (1994).
   Google Scholar
• BAKKER K, RILEY G: (1994). Computerized Scoring of Stuttering Severity. Austin, TX ProEd.
   Google Scholar
• BRADY JP: The pharmacology of stuttering: a critical review.Am. J. Psychiatry (1991) 148:1309–1316.
   PubMed Web of Science ®Google Scholar
• COSTA D: Antidepressants and the treatment of stuttering [letter; comment]. Am. J. Psychiatry (1992) 149(9):1281.
   PubMed Web of Science ®Google Scholar
• STAGERS, CALIS K, GROTHE D et al: A double-blind trial of pimozide and paroxetine for stuttering. In: Speech Production: motor control, brain research and fluency disorders. Hulstijn W, Peters HRM, Van Lieshout PHHM (Eds). International Congress Series 1146. Excerpta Medica, Amsterdam, The Netherlands (1997):379–382.
   Google Scholar
• BRADY JP, MCALLISTER TW,PRICE, TR: Verapamil in stuttering [letter].Biol. Psychiatry (1990) 27(6):680–681.
   Google Scholar
• MAGUIRE G, RILEY G, HAHN R, PLON L: Nimodipine in the treatment of stuttering. ASHA Journal (1994) 36:51.
   PubMedGoogle Scholar
• MARGOLESE HC, ANNABEL L, DION Y: Depression and dysphoria in adult and adolescent patients with Tourette syndrome treated with risperidone. Presented at the American College of Neuropsychopharmacology Waikoloa, HI, USA. December 10, (2001).
   Google Scholar
• LAVID N, FRANKLIN DL,MAGUIRE, GA: Management of child and adolescent stuttering with olanzapine: three case reports. Ann. Clin. Psychiatry (1999) 11(0233–236.
   PubMedGoogle Scholar
• MAGUIRE et al.: Olanzapine in the treatment of adult developmental stuttering. Presented at the American College of Neuropsychopharmacology Waikoloa, Hawaii. December 10 (2001).
   Google Scholar
• MAGUIRE GA, RILEY GD,FRANKLIN DL et al.: Olanzapine in the treatment of developmental stuttering: a double-blind, placebo-controlled trial. Ann. Clin. Psychiatry (In Press).
   Google Scholar
• YANNATOS G: L'hydroxyzine dans la therapeutique des bégaiements. J. Fr. Otorhinolaryngol Chir. Maxillofac. (1960) 9:293-296 (French).
   Google Scholar
• MAGUIRE G, YARUSS S: NSA Convention. Anaheim, CA June (2002).
   Google Scholar
• BOBERG E, KULLY D: Long-term results of an intensive treatment program for adults and adolescents who stutter. Speech Hear. Res. (1994) 37(5):1050–1059.
   PubMedGoogle Scholar
• MANNING, WH: Clinical decision making in fluency disorders,second ed. Calgary, Canada: Singular (2001).
   Google Scholar
• BRIT J: Management of weight gain associated with antipsychotics. Ann. Clin. Psychiatry (2003) 15(1):49–58 (Review).
   Google Scholar
• YU BP, MAGUIRE, GA, LIFFICK T: `Modafinil as a treatment for negative symptoms of schizophrenia and antipsychotic-associated weight gain. Institute Psychiatr. Serv. (2001) 53:44 (Abstract).
   Google Scholar
• MEYER JMA: Retrospective comparison of weight, lipid, and glucose changes between risperidone- and olanzapine-treated inpatients: metabolic outcomes after 1 year.Clin. Psychiatry (2002) 63(5):425–433.
   Google Scholar
• BRADY JP, ALI Z: Alprazolam, citalopram, and clomipramine for stuttering. j Clin. Psychopharmacol (2000) 20(2):287.
   PubMed Web of Science ®Google Scholar